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Abstract
AHNAK/Desmoyokin is a giant protein which has been recently linked to reorganization of the actin cytoskeleton, cellular
migration and invasion. Here, we investigated the role of AHNAK in the pathophysiology of larynx carcinoma-one of the
major subtypes of head and neck cancer. To this end, we analysed AHNAK expression in tumor tissues from 83 larynx
carcinoma patients in relation to overall survival. We found that tumoral AHNAK overexpression significantly associated with
poor survival of these patients both in univariate and multivariate analysis. In further studies, we combined the prognostic
value of AHNAK with selected markers of inflammation, such as macrophage migration inhibitory factor (MIF) and tumor-
infiltrating neutrophils (CD66b-positive cells). Both MIF and neutrophils have been linked to enhanced tumoral migration
and poor clinical outcome in patients with orohypopharynx carcinoma-another major subtype of head and neck cancer.
Interestingly, we found that synchronous high levels of AHNAK and MIF or AHNAK and neutrophils, respectively, were
stronger predictors of poor survival than AHNAK alone. Synchronous high levels of all three markers were the strongest
predictors of poor survival in our patient cohort. Taken together, our findings propose novel strategies for an accurate
prognosis in larynx carcinoma and suggest potential mechanisms of inflammation-mediated tumor progression.
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Introduction
Head and neck cancer (HNC) is the eighth most common type
of cancer worldwide. Despite multiple and aggressive therapeutic
interventions, there has been no fundamental improvement in the
5-year survival rates of the patients over the past decades [1,2].
Therefore, there is an urgent need to: i) identify clinicopathological
factors for accurate diagnosis, prognosis and therapeutic predic-
tion in these patients and to ii) understand the biology and
molecular mechanisms behind the respective factors.
AHNAK (desmoyokin) is a protein of exceptionally large size
(700 kDa) that is expressed in a variety of cell types [3]. Early
studies proposed that AHNAK localized mainly in the nuclei-a
potential consequence of the nuclear localization sequences (NLSs)
present in the carboxy-terminal domain of the protein [4].
Additionally, it was proposed that AHNAK might associate with
the Golgi network [4], although later studies did not observe co-
localization of AHNAK with Golgi markers such as mannosidase
II or tgn38 [5]. Other studies reported that AHNAK localized in
the cytoplasm and/or associated with the plasma membrane [6,7].
The apparent discrepancy regarding the localization of AHNAK
might be explained by the ability of this protein to shuttle between
various subcellular compartments. For instance, it has been shown
that AHNAK can translocate from the cytoplasm to the plasma
membrane of keratinocytes in a manner dependent on Ca2+ and
Protein Kinase C [7]. Furthermore, AHNAK was shown to
contain a nuclear export signal (NES) sequence which ‘allowed’ it
to be excluded from the nuclei of epithelial cells following cell-cell
contact and activation of Protein Kinase B, respectively [8]. At
functional level, AHNAK was shown to be involved in various
cellular processes, including calcium regulation and organization
of the actin cytoskeleton [9,10]. In tumor cells, AHNAK was
recently found to be essential for pseudopodia formation and
tumoral migration/invasion [11]. Other recent studies proposed
that the AHNAK gene might be involved in mutagenic
transformation of colon epithelial cells and, thus, carcinogenesis
[12]. A potential role of AHNAK as prognostic marker for survival
in cancer patients has, however, never been shown thus far.
Presently, it is well established that solid tumors display an
inflammatory microenvironment characterized by large numbers
of tumor-infiltrating immune cells [13]. Within this microenvi-
ronment, the immune cells of the host are ’reprogrammed’ by the
tumor cells to acquire pro-tumoral activities. Although less
characterized than tumor-associated macrophages (TAMs) or
tumor-infiltrating lymphocytes (TILs), tumor-infiltrating neutro-
phils are emerging as important players in the pathophysiology of
cancer. Within the tumor tissue, neutrophils can modulate several
cellular processes which may ultimately lead to tumor progression.
Neutrophils were shown to modulate angiogenesis in several
murine tumor models [14,15,16] and were recently associated
with angiogenesis progression in hepatocellular carcinoma patients
[17]. Further studies showed that neutrophils could directly
modulate the biology and functions of tumor cells by promoting
their migration, invasion or proliferation (reviewed in [18]). Thus,
it is not surprising that very recent studies reported an association
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of high numbers of tumor-infiltrating neutrophils with advanced
disease and poor clinical outcome in patients with different types
of cancer, such as renal cancer, hepatocellular cancer, non-small-
cell lung carcinoma (NSCLC) or melanoma (reviewed in [19]).
Recently, we demonstrated that high neutrophilic infiltration of
the tumor tissue associated with high tumor (T) stage and poor
survival in head and neck (orohypopharynx) cancer patients with
advanced disease [20]. Furthermore, our in vitro studies indicated a
direct interaction between neutrophils and head and neck cancer
cells by showing that neutrophils were ‘primed’ by the tumor cells
to release pro-inflammatory factors which promoted tumoral
migration in a feed-back manner [21,22].
The exact molecular mechanisms responsible for tumor-host
interactions in head and neck and other types of cancer have been
only partially clarified. Selected soluble inflammatory mediators,
such as cytokines, chemokines and metabolites of the arachidonic
acid pathway, have been found to change the function and
differentiation of immune cells [23]. Among these molecules,
macrophage migration inhibitory factor (MIF) is emerging as an
important regulator of inflammation in cancer [24]. A number of
studies found that high levels of MIF in the tumor tissues or serum
of patients with different types of cancer associated with advanced
disease and poor clinical outcome (reviewed in [25]). Recent
studies from our group demonstrated that overexpression of
Figure 1. AHNAK, MIF and CD66b expression and scoring in larynx carcinoma tissues. (A) Malignant laryngeal and healthy epithelial
tissues were stained against AHNAK and MIF. The immunoreactive score (IRS) was calculated as intensity of the staining reaction multiplied by the
percentage of positive cells. Based on the IRS values, AHNAK and MIF were scored as weak, medium and strong. (B) Representative micrographs
indicating that strong levels of AHNAK are found only in malignant tissues, while healthy epithelial tissues displayed either weak or medium levels of
AHNAK. Consequently, the weak and medium AHNAK-expressing specimens were considered as ‘AHNAKlow’ while strong AHNAK-expressing
specimens were termed ‘AHNAKhigh’. (C) Representative micrographs indicating that medium and strong levels of MIF are found only in malignant
tissues, while healthy epithelial tissues displayed weak levels of MIF. Consequently, the weak MIF-expressing specimens were considered as ‘MIFlow’
while medium and strong MIF-expressing specimens were termed ‘MIFhigh’. (D) Representative micrographs showing negative, weak, medium and
strong infiltration of larynx carcinoma tissues by neutrophils (CD66b-positive cells). Negative and weak samples were considered as CD66blow while
medium and strong samples as CD66bhigh. Scale bars are indicated in the upper-left corner of each figure and apply for all panels of the respective
figure.
doi:10.1371/journal.pone.0056420.g001
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tumoral MIF associated with poor overall survival in patients with
orohypopharyngeal cancer [21]. More importantly, we identified
MIF as one of the ’missing links’ in the tumor-neutrophil
interraction and showed that head and neck cancer cells released
MIF which, subsequently, enhanced the proinflammatory func-
tions of neutrophils to promote tumoral migration [21].
This study investigated the relevance of AHNAK, MIF and
tumor-infiltrating neutrophils (CD66b-positive cells) for the
survival of patients with laryngeal carcinoma-a major subtype of
head and neck cancer. We demonstrated that AHNAK overex-
pression significantly associated with poor survival in these
patients. Interestingly, we found that high levels of AHNAK
together with high MIF expression or high neutrophilic infiltra-
tion, respectively, were stronger associated with poor survival than
AHNAK alone. Synchronous high levels of MIF and tumor-
infiltrating neutrophils had stronger predictor values over the
individual markers as well. Finally, patients with high levels of all
three markers displayed the shortest survival in the entire patient
cohort. Thus, our study proposes novel strategies for a more
accurate prognosis in larynx carcinoma and suggests potential
mechanisms of inflammation-mediated tumor progression.
Materials and Methods
Study subjects
Tissue microarrays (TMAs) were obtained from 83 patients with
head and neck squamous cell carcinoma of the larynx. The
patients were treated at the Department of Otorhinolaryngology
(University of Duisburg-Essen) between 1995 and 2002, and
clinical follow-up was retrieved. Patient characteristics are
summarized in Table 1. Healthy epithelial tissues were obtained
from tonsils or palatine uvulas following tonsillectomy or
uvulopalatopharyngoplasty (UPPP), respectively. All studies were
approved by the ethics committee of the University Hospital Essen
(nr. 12-5192-BO). The data were analysed anonymously and the
ethics committee provided a waiver of the need for informed
consent.
Antibodies and reagents
Polyclonal rabbit anti-human AHNAK antibodies (catalog
number HPA019070) were obtained from Sigma (St. Louis,
MO, USA). Monoclonal mouse anti-CD66b antibodies clone
80H3 (catalog number IM0166) were from Immunotech (Mar-
seille Cedex, France). Monoclonal mouse anti-MIF antibodies
(catalog number MAB289) were obtained from R&D Systems
(Abingdon, United Kingdom).
Tissue microarrays: construction and
immunohistochemical analysis
Tissue cores with a diameter of 3 mm were extracted from
formalin-fixed/paraffin-embedded tumor tissue blocks using a skin
biopsy punch (PFM, Cologne, Germany). The tissue cores were
then brought into recipient blocks and cut into 5 mM sections.
Antigen retrieval was performed by HIER (Heat-Induced Epitope
Retrieval) in citrate buffer pH 6.0. Samples were stained with 0.6
mg/ml anti-AHNAK antibodies using an automated staining
device (Dako Autostainer; DakoCytomation, Hamburg, Ger-
many). Secondary and tertiary immunoreactions were performed
with a commercially available anti-rabbit IgG detection kit (En-
Vision; DakoCytomation, Hamburg, Germany). Colorimetric
reactions were developed with diamino-benzidine (DAB). Staining
of TMAs with anti-MIF and anti-CD66b antibodies, respectively,
has been described previously [20,21]. Analysis was performed
with a Zeiss Axioscope 2 microscope at 2006(AHNAK and MIF)
and 4006(CD66b) magnification, respectively. Blinded scoring
was performed independently by authors C.A.D., X.G. and A.B.
(senior histopathologist).
AMIDA screening
Tumors elicit an immune response, leading to the generation of
antibodies specific for tumoral antigens. AMIDA technology
(autoantibody-mediated identification of antigens) identifies pro-
teins preferentially recognized by antibodies from cancer patients
over those from healthy controls. Here, we used AMIDA to screen
for tumor-associated antigens in 4 head and neck cancer patients
versus 4 healthy donors, as previously described [26]. Briefly,
plasma antibodies were isolated using Protein G Montage spin
columns (Millipore, Billerica, USA). Purified antibodies were
covalently coupled to protein G beads (Amersham Biosciences,
Freiburg, Germany) and incubated with cell lysates from FaDu
cells. Bound proteins were eluted into 2D lysis buffer (9 M urea,
4% v/v Chaps, 2.5 mM EDTA). Isoelectric focusing was done on
IPGphor system using pH 4–7 IPG strips (GE Healthcare) and
Table 1. Characteristics of the patients used for analysis of
AHNAK, MIF and CD66b, indicating number, gender, TNM
stage, histological grading and AJCC stage.
patients per group
Patient characteristics number % of total
all patients 83 100
gender
male 78 94.0
female 5 6.0
T- stage
T1 14 16.9
T2 26 31.3
T3 25 30.1
T4 18 21.7
N- stage
N0 54 65.1
N1 10 12.0
N2a 0 0
N2b 10 12.0
N2c 9 10.8
N3 0 0
distant metastasis
M0 83 100
M1 0 0
differentiation grade
grade 1 6 7.2
grade 2 64 77.1
grade 3 13 15.7
AJCC- stage
stage I 12 14.5
stage II 21 25.3
stage II 22 26.5
stage IV 28 33.7
doi:10.1371/journal.pone.0056420.t001
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proteins were separated on a vertical 12% PAGE in an Ettan Dalt
II unit (GE Healthcare, Freiburg, Germany). Differentially
precipitated protein spots were excised and analyzed. Mass
spectrometry was performed at the Protein Analysis Unit at the
Ludwig-Maximilians-University of Munich.
Statistical analysis
Clinical data were analysed with the SPSS statistical software
version 18.0 (SPSS Inc, Chicago, IL, USA). Survival curves (5-
years cutoff) were plotted according to the Kaplan-Meier method.
Significance was initially tested in univariate analysis using the log-
rank test or univariate Cox regression. Multivariate analysis was
used to determine the independent prognostic value of selected
variables using Cox’s proportional hazards linear regression
model. In all studies, the level of significance was set at p#0.05.
Results
AHNAK, MIF and CD66b in larynx carcinoma: expression
and scoring system
Using AMIDA technology we initially screened for novel
tumor-associated antigens (TAAs) in sera from head and neck
cancer patients and we identified AHNAK as a potential
candidate (see Materials and Methods section). Next, we
determined the expression of AHNAK at protein level by
immunohistochemical analysis of tissue microarrays (TMAs) from
83 larynx carcinoma patients. As control, AHNAK expression was
determined in healthy epithelial tissues from tonsil (n = 9) and
palatine uvula (n = 3). AHNAK expression was scored as intensity
of staining multiplied by the percentage of positive cells
(IRS= immunoreactive score) (Figure 1A). An IRS of 1–4 was
considered as weak AHNAK, IRS 6–8 as medium and IRS 9–12
represented strong AHNAK levels (Figure 1A). In healthy epithelial
tissues we observed weak and medium levels of AHNAK, but no
strong AHNAK expression (Figure 1B). Consequently, we consid-
ered that weak and medium AHNAK represent basal levels of the
protein (from here on termed ‘AHNAKlow’), while strong AHNAK
represents overexpressed levels of the protein (from here on
termed ‘AHNAKhigh’).
In another set of studies we stained TMAs from the same
patients as above against selected markers of inflammation. We
chose MIF and CD66b (neutrophil marker) because they have
been shown to associate with advanced disease and poor survival
in orohypopharynx carcinoma patients-another major subtype of
head and neck cancer [20,21]. Expression of MIF, likewise that of
AHNAK, was initially scored based on the IRS system (see above).
However, in healthy epithelial tissues we only found MIF to be
weakly expressed (Figure 1C). Consequently, we considered that
weak MIF represents basal levels of the protein (from here on
termed ‘MIFlow’), while medium and strong MIF represent overex-
pressed levels of the protein (from here on termed ‘MIFhigh’). The
levels of tumor-infiltrating neutrophils (CD66b-positive cells) were
initially assessed as negative, weak, medium and strong (Figure 1D). For
the final statistical analysis the negative and weak CD66b samples
were considered as CD66blow, while the medium and strong samples
were considered as CD66bhigh, as previously published [20].
AHNAK, MIF and CD66b in larynx carcinoma: univariate
analysis of survival
In further studies, we determined whether there might be a
relationship between expression levels of AHNAK, MIF or CD66b
and 5-years overall survival of larynx carcinoma patients. To this
end, survival curves were plotted according to the Kaplan-Meier
method and significance was tested by log-rank test. The results
showed that patients with high levels of AHNAK (AHNAKhigh) or
CD66b (CD66bhigh) had significantly shorter survival than
AHNAKlow or CD66blow patients (p = 0.021 and p=0.048,
respectively; log-rank) (Figures 2A and 2C). Patients with high
levels of MIF (MIFhigh) tended to have worse survival than those
with MIFlow (p = 0.072; log-rank) (Figure 2B); however a larger
Table 2. Univariate Cox regression analysis for survival in patients with different combinations of AHNAK/MIF, AHNAK/CD66b and
MIF/CD66b.
Hazard ratio for survival patients per group
Cox regression univariate HR 95% CI p-value number % of total
AHNAK MIF
low low 1 32 42.1
low high 1.34 0.55–3.23 0.509 27 35.5
high low 1.37 0.30–6.27 0.681 5 6.57
high high 3.48 1.40–8.61 0.007 12 15.7
AHNAK CD66b
low low 1 23 30.6
low high 2.47 0.89–6.88 0.083 35 46.6
high low 3.38 0.98–11.72 0.054 9 12
high high 5.96 1.80–19.78 0.003 8 10.6
CD66b MIF
low low 1 20 25.9
low high 2.06 0.63–6.77 0.232 14 18.1
high low 1.99 0.63–6.28 0.237 18 23.3
high high 3.41 1.22–9.53 0.019 25 32.4
HR= hazard ratio; 95% CI = 95% confidence interval. Significant values are indicated by asterisks (*).
doi:10.1371/journal.pone.0056420.t002
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cohort of patients might be needed to reach statistical significance
for MIF.
Next, we investigated the relevance of AHNAK, MIF and
CD66b taken in combination regarding survival of larynx
carcinoma patients. To this end, we divided our cohort of patients
into 4 groups for each combination of markers (i.e. AHNAKlow/
MIFlow, AHNAKlow/MIFhigh, AHNAKhigh/MIFlow and AHNA-
Khigh/MIFhigh). Similar groups were built for AHNAK/CD66b
and for CD66b/MIF, respectively. We plotted Kaplan-Meier
survival curves for the above-mentioned marker combinations
(Figure 3A–C) and observed that patients with ’double-high’
phenotype had consistently shorter overall survival than their
counterparts (Figure 3A–C). To test the significance of these
results, we performed univariate Cox regression analysis for overall
survival. The groups with ‘double-low’ phenotype were considered
as the dummy variable (value = 1). As indicated in Table 2,
patients with synchronous high levels of AHNAK/MIF
(HR=3.48, 95% CI=1.40–8.61, p = 0.007), AHNAK/CD66b
(HR=5.96, 95% CI=1.80–19.78, p = 0.003) and CD66b/MIF
(HR=3.41, 95% CI= 1.22–9.53, p = 0.019) had significantly
higher hazard of death than the other groups of patients (Table 2).
AHNAK, MIF and CD66b in larynx carcinoma: multivariate
analysis of survival
In further studies we sought to confirm the relative values of
AHNAK, MIF and CD66b as prognostic markers in larynx
carcinoma by multivariate survival analysis using Cox regression
model. To build this model, we tested what other factors might
influence survival in our patient cohort and, consequently, plotted
Kaplan-Meier curves for tumor stage (T-stage), lymph node
Table 3. Multivariate Cox regression analysis for AHNAK, MIF and CD66b taken individually or in combination.
Hazard ratio for survival patients per group
Cox regression multivariate HR 95% CI p-value number % of total
AHNAK
low 1 59 72.8
high 3.17 1.45–6.94 0.004 22 27.2
MIF
low 1 40 50.0
high 1.76 0.87–3.56 0.113 40 50.0
CD66b
low 1 35 43.7
high 1.98 0.93–4.18 0.073 45 56.3
AHNAK MIF
low low 1 32 42.1
low high 1.23 0.51–2.97 0.639 27 35.5
high low 1.73 0.37–8.06 0.484 5 6.57
high high 4.40 1.71–11.30 0.002 12 15.7
AHNAK CD66b
low low 1 23 30.6
low high 2.83 0.97–8.22 0.083 35 46.6
high low 5.13 1.36–19.27 0.015 9 12.0
high high 8.17 2.26–29.45 0.001 8 10.6
CD66b MIF
low low 1 20 25.9
low high 2.19 0.65–7.32 0.203 14 18.1
high low 2.47 0.75–8.13 0.135 18 23.3
high high 3.55 1.21–10.40 0.021 25 32.4
AHNAK CD66b MIF
low low low 1 15 16.9
low high low 3.28 0.77–13.97 0.107 17 23.3
low low high 1.82 0.29–11.28 0.520 8 11.0
low high high 4.00 0.98–16.35 0.053 18 24.7
high low low 2.13 0.21–20.78 0.514 3 4.1
high high low 7.09 1.48–34.03 0.014 6 8.2
high low high 4.84 0.48–48.42 0.180 2 2.7
high high high 13.80 2.98–63.87 0.001 5 6.8
HR= hazard ratio; 95% CI = 95% confidence interval. Significant values are indicated by (*).
doi:10.1371/journal.pone.0056420.t003
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metastasis (N-stage), AJCC stage and histological grading
(Figure 4). We found that T-stage (Figure 4A) as well as AJCC
stage (Figure 4C) were significantly associated with overall survival
(p = 0.048 and p= 0.040, respectively; log-rank). Next, we adjusted
our multivariate model for T- and AJCC-stage and tested the
significance of AHNAK, MIF and CD66b as single parameters or
in combination. The results showed that, when analysed
individually, AHNAK remained a strong and significant prognos-
tic marker (HR=3.17, 95% CI= 1.45–6.94, p= 0.004) (Table 3).
Similarly, patients with synchronous high levels of AHNAK/MIF
(HR=4.40, 95% CI= 1.71–11.30, p= 0.002), AHNAK/CD66b
(HR=8.17, 95% CI= 2.26–29.45, p = 0.001) and CD66b/MIF
(HR=3.55, 95% CI= 1.21–10.40, p = 0.021) continued to exhibit
significantly higher hazard of death compared to their counter-
parts (Table 3).
Finally, we performed exploratory studies to determine the
prognostic value of all three markers taken in combination (8
combinations) for the survival of larynx carcinoma patients.
Interestingly, Kaplan-Meier analysis showed that the patients with
synchronous high expression of all markers (AHNAKhigh/
CD66bhigh/MIFhigh) had the shortest overall survival in our
patient cohort (p = 0.006; log-rank) (Figure 5A). These results
were further strengthened by multivariate Cox regression analysis
which demonstrated that patients with the ‘triple-high’ phenotype
had the highest risk of death (HR=13.80, 95% CI= 2.98–63.87,
p = 0.001) compared to the other groups of patients (Table 3).
Discussion
Increased effort has been made to identify cellular/molecular
factors that could provide accurate information regarding cancer
diagnosis, prognosis and response to therapy. In this study, we
identified AHNAK as a novel independent prognostic factor for
the overall survival of larynx carcinoma patients. Furthermore, we
demonstrated that combined analysis of inflammatory markers
(MIF and CD66b) with AHNAK or with one another has higher
significance regarding survival than analysis of the individual
markers. Thus, our study proposes novel strategies for a more
accurate prognosis in larynx carcinoma and suggests potential
mechanisms of tumor progression.
The role of AHNAK in cancer is poorly characterized at
present. In fact, a very recent PubMed search using the keywords
’AHNAK’ or ‘desmoyokin’ and ’cancer’ resulted in less than 20
hits. Most of the studies on this topic were performed in vitro, on
Figure 2. Univariate analysis of survival for AHNAK, MIF and
tumor-infiltrating neutrophils in larynx carcinoma patients.
Kaplan-Meier 5-years survival curves were plotted for patients with low
versus high levels of (A) AHNAK, (B) MIF and (C) tumor-infiltrating
neutrophils (CD66b). Statistical testing was performed with the log-rank
test.
doi:10.1371/journal.pone.0056420.g002
Figure 3. Combined analysis of AHNAK, MIF and tumor-
infiltrating neutrophils regarding survival of larynx carcinoma
patients. Larynx carcinoma patients were divided into 4 groups for
each combination of markers and survival curves were plotted
according to the Kaplan-Meier method. (A) combined analysis of
AHNAK and MIF, (B) combined analysis of AHNAK and CD66b and (C)
combined analysis of CD66b and MIF. Statistical analysis was performed
by univariate Cox regression and the results are summarized in Table 2.
doi:10.1371/journal.pone.0056420.g003
Novel Prognostic Markers in Larynx Cancer
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e56420
cancer cell lines and/or investigated AHNAK at gene rather than
at protein level [11,12,27]. In our study, we analysed the
expression levels of AHNAK by immunohistochemistry in tumor
tissues from 83 larynx carcinoma patients. The results demon-
strated that overexpression of tumoral AHNAK was strongly and
significantly associated with poor survival of these patients, both in
univariate and multivariate analysis. Thus, to the best our
knowledge, we are the first to investigate AHNAK in a patient
cohort of relevant size. Most importantly, our study is the first to
identify AHNAK as a potential prognostic marker in cancer.
Of particular interest and novelty are also our findings
regarding combination of inflammatory markers with AHNAK.
In this study we tested the relevance of tumoral MIF and of tumor-
infiltrating neutrophils (CD66b-positive cells) for the survival of
larynx carcinoma patients. Both MIF and neutrophils have been
previously linked to poor clinical outcome in orohypopharynx
carcinoma patients [20,21]. Our results showed that combined
analysis of these markers with AHNAK associated strongly with
poor survival in larynx carcinoma patients. Specifically, we found
that patients with high AHNAK and high MIF levels (AHNA-
Khigh/MIFhigh) or high neutrophilic infiltration (AHNAKhigh/
CD66bhigh), respectively, had significantly shorter overall survival
than the other groups of patients. Furthermore, the statistical
significance of these combinations was stronger than that of the
highly significant AHNAK. Thus, our findings indicate that
combined analysis of AHNAK with either MIF or CD66b might
be a good strategy for an accurate prognosis in larynx carcinoma
patients.
Additionally, these findings suggest that AHNAK might
’cooperate’ with MIF and/or neutrophils to enhance progression
of larynx carcinoma. A synergistic effect between cellular and
molecular factors regarding tumor progression is supported by
combined analysis of MIF and neutrophils in our cohort of
patients. Specifically, we observed that synchronous high levels of
neutrophilic infiltration and of MIF (CD66bhigh/MIFhigh) were
significantly associated with poor survival, although the individual
markers were less so. These findings indicate that MIF and
neutrophils might interact with each other in the tumor
microenvironment to enhance the progression of larynx carcino-
ma. Recently, our group identified direct interactions between
head and neck cancer (HNC)-derived MIF and neutrophils both in
vitro and in situ. We showed that HNC-derived MIF enhanced
neutrophil chemotaxis in vitro and that tumoral MIF levels
correlated with the neutrophilic infiltration in tissues from
orohypopharynx carcinoma patients [21]. Since MIF is a known
ligand for CXCR2-one of the major chemokine receptors on
neutrophils [28], MIF-mediated recruitment might be a critical
mechanism for infiltration of HNC tissues by neutrophils. Our
studies further demonstrated that HNC-derived MIF stimulated
neutrophils to release large amounts of pro-inflammatory factors,
among which CCL4 and MMP9 [21]. Importantly, the factors
released by neutrophils upon HNC stimulation enhanced tumoral
Figure 4. Univariate analysis of survival for other potentially-relevant clinical parameters in larynx carcinoma patients. Kaplan-Meier
5-years survival curves were plotted for patients with (A) low versus high T-stage, (B) presence or absence of lymph node metastasis, (C) low versus
high AJCC stage and (D) well-, moderately- and poorly-differentiated tumors. Statistical testing was performed with the log-rank test.
doi:10.1371/journal.pone.0056420.g004
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migration in a feedback manner [21]. These findings are
supported by an increasing number of studies showing that
neutrophils enhance the motility, migration and invasion of tumor
cells via-thus far not fully identified-soluble factors and molecular
mechanisms (reviewed in [19,29]). Interestingly, AHNAK was
recently linked to regulation of tumoral migration/invasion, when
Shankar and co-workers elegantly demonstrated that AHNAK
was essential for rearrangement of the actin cytoskeleton and
pseudopodia formation [11]. Based on the above-mentioned
findings, it would be tempting to hypothesize that neutrophils
might enhance tumoral migration/invasion via AHNAK. If this
hypothesis proves correct, the progression of larynx carcinoma
could be modulated by interactions between all three ‘players’
(Figure 5B). Such a model seems to be supported by our
exploratory studies showing that synchronous high expression of
the three markers (AHNAKhigh/CD66bhigh/MIFhigh) associates
with the shortest overall survival in larynx carcinoma patients.
These findings need, however, to be confirmed on larger cohorts
of patients and (some) of the proposed interactions have yet to be
addressed and proven experimentally in future studies.
In summary, our study identifies novel molecular and cellular
factors that might serve as prognostic biomarkers and might
interact with each other to enhance progression of laryngeal
cancer. Ultimately, these findings contribute to a better under-
standing and foster the development of improved therapeutic
strategies against larynx carcinoma and, perhaps, other types of
solid cancer as well.
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